KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $28.6 million.

  • Nektar Therapeutics' Accumulated Expenses fell 1168.42% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year decrease of 1168.42%. This contributed to the annual value of $30.0 million for FY2024, which is 3524.05% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Accumulated Expenses is $28.6 million, which was down 1168.42% from $35.1 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Accumulated Expenses peaked at $37.4 million during Q1 2023, and registered a low of $15.7 million during Q4 2021.
  • Its 5-year average for Accumulated Expenses is $28.6 million, with a median of $29.5 million in 2024.
  • In the last 5 years, Nektar Therapeutics' Accumulated Expenses surged by 13232.92% in 2022 and then crashed by 3937.69% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Accumulated Expenses (Quarter) stood at $15.7 million in 2021, then skyrocketed by 132.33% to $36.6 million in 2022, then plummeted by 39.38% to $22.2 million in 2023, then soared by 35.24% to $30.0 million in 2024, then dropped by 4.6% to $28.6 million in 2025.
  • Its Accumulated Expenses stands at $28.6 million for Q3 2025, versus $35.1 million for Q2 2025 and $31.3 million for Q1 2025.